SV

Street Verdict

Analyst Scorecard

METROPOLIS · NSE

Metropolis Healthcare Limited

₹566

+1.31% (+₹7.3)

Prev. close

₹558.7

Volume

2,85,857

Delivery %

58.2%

As of

20 Nov 2026

Price history

₹566+₹14.05 (+2.55%) · 3M
18 Aug 2026 → 20 Nov 2026
52054056058060018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Metropolis Healthcare Limited

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including X-ray, sonography and ECG; and next-generation sequencing services. It also provides diagnostic services for oncology, chronic and infectious diseases, gastroenterology, neurology, nephrology, and women and child health, as well as various health checkup and laboratory services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, mobile app, website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Details

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Ms. Ameera Sushil Shah

Headquarters

Mumbai

Employees

4,484

Key stats

Market cap

₹11,997.25 Cr

P/E ratio (TTM)

53.6

Dividend yield

0.35%

EPS (TTM)

₹10.78

Beta (1Y · daily vs NIFTY 50)

0.46

Beta (5Y · monthly vs NIFTY 50)

0.91

Shares float

10.61 Cr

EPS · quarter ended Jun 2026

₹2.73

Upcoming earnings

03 Feb 2027

Financial Performance

01 · Financials

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹0%5%10%15%20%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

051015₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

01122₹-100%-50%0%50%13 Feb 2017 Feb 2121 Feb 2223 Feb 2317 Nov 2311 Nov 2519 May 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-200%0%200%400%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr100 Cr200 Cr300 Cr400 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹997.99 Cr₹1,228.34 Cr₹1,148.21 Cr₹1,207.71 Cr₹1,331.20 Cr₹1,645.85 Cr
EBITDA
₹298.05 Cr₹376.32 Cr₹303.52 Cr₹291.69 Cr₹318.11 Cr₹417.44 Cr
₹183.10 Cr₹214.18 Cr₹142.88 Cr₹127.82 Cr₹144.97 Cr₹190.02 Cr
Diluted EPS
₹8.95₹10.42₹6.95₹6.22₹7.04₹9.19

EBITDA for Mar 2022 could not be checked against the company's own annual report: this page shows ₹376.32 Cr while the annual report gives ₹360.42 Cr (4.2% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹241.39 Cr) is left blank here too, rather than shown from only one of the two sources.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,000.00 Cr₹1,521.00 Cr₹1,495.00 Cr₹1,547.00 Cr₹1,859.00 Cr₹2,131.00 Cr
₹112.27 Cr₹378.56 Cr₹266.38 Cr₹197.06 Cr₹204.13 Cr₹231.91 Cr
Stockholders' equity
₹706.00 Cr₹886.00 Cr₹988.00 Cr₹1,096.00 Cr₹1,331.00 Cr₹1,513.00 Cr

CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹249.00 Cr₹253.00 Cr₹247.00 Cr₹264.00 Cr₹263.00 Cr₹351.00 Cr
Investing cash flow
₹61.70 Cr₹-735.05 Cr₹46.79 Cr₹-89.41 Cr₹-201.06 Cr₹-223.13 Cr
₹-33.00 Cr₹163.00 Cr₹-292.00 Cr₹-181.00 Cr₹-87.00 Cr₹-115.00 Cr
Capital expenditure
₹-28.27 Cr₹-30.66 Cr₹-52.63 Cr₹-63.76 Cr₹-68.61 Cr₹-51.18 Cr
End cash position
₹386.59 Cr₹65.98 Cr₹68.83 Cr₹62.62 Cr₹39.48 Cr₹54.78 Cr

Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22–Jun 22(2Q)Sep 22–Dec 22(2Q)Mar 23–Jun 23(2Q)Sep 23–Dec 23(2Q)Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25–Sep 25(2Q)Dec 25Mar 26–Mar 26(2Q)Jun 26
Promoter50.33%49.50%49.79%49.76%49.75%49.74%49.67%49.62%49.43%49.40%48.90%48.89%48.88%48.87%48.86%
Public49.67%50.50%50.21%50.24%50.25%50.26%50.33%50.38%50.57%50.60%51.10%51.11%51.12%51.13%51.14%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Metropolis Healthcare Limited₹11,849.27 Cr₹581.2553.07.8312.6%0.15+23.6%-71.4%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

METROPOLIS

Metropolis expects FY27 growth and margin momentum to persist

Multibagg AI · 13 days ago

METROPOLIS

Metropolis Healthcare Q2: Net profit jumps 43% on higher test volumes, specialty and B2C growth

CNBC TV18 · 19 days ago